DeviceClearance

NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced Therapy System, NeuroStar TMS Therapy System, NeuroStar Advanced Therapy for Mental Health, NeuroStar— 510(k) K212289

Substantially Equivalent

Neuronetics, Inc.

FDA 510(k) clearance K212289 for NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced Therapy System, NeuroStar TMS Therapy System, NeuroStar Advanced Therapy for Mental Health, NeuroStar, Substantially Equivalent on 2022-05-06. Applicant: Neuronetics, Inc..

Clearance details

Applicant
Neuronetics, Inc.
Product code
Code QCI
Advisory panel
Neurology
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Malvern, PA, US
Download summary PDFView on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.